Clinical Trial Update: RANK-ligand Inhibition to Combat Sarcopenia with Underlying Osteoporosis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating RANK-ligand inhibition to treat sarcopenia with underlying osteoporosis is currently recruiting in Hong Kong.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Sarcopenia

Drugs mentioned

• Denosumab (denosumab)

Snippet

Sponsor: Prince of Wales Hospital, Shatin, Hong Kong | Conditions: Sarcopenia in Elderly | Phase 4 | Status: RECRUITING